Clinical research of medical ovarian suppression combined with anastrozole in the treatment of metastatic breast cancer in premenopausal women
10.3760cma.j.issn.1006-9801.2012.06.010
- VernacularTitle:药物性卵巢去势联合阿那曲唑治疗绝经前转移性乳腺癌患者的临床研究
- Author:
Qian LIU
;
Tao WANG
;
Zefei JIANG
;
Min ZENG
;
Shaohua ZHANG
;
Shikai WU
- Publication Type:Journal Article
- Keywords:
Metastatic breast neoplasms;
Endocrine therapy;
Anastrozole;
Goserelin
- From:
Cancer Research and Clinic
2012;24(6):392-394
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the correlation of the clinical effects and prognosis in patients receiving medical ovarian suppression (goserelin)combined with anastrozole treatment with premenopausal metastatic breast cancer.Methods 44 hormone dependent mastatic breast cancer patients were treated by goserelin,3.6mg hypodermic injection every 28 days and anastrozole 1 mg were administered orally,clinical effects and prognosis were analysed.Results The clinical benefit rates of goserelin combination with anastrozole in patients with metastatic breast cancer were 52.4 ％(23/44),and the median progression free survival (PFS)was 8.3(5.3-11.2)months.In the analysis of whether to accept chemotherapy,the PFS of the not received chemotherapy group was better than received chemotherapy group (16.9 months vs 5.8 months P=0.048).Conclusion The combination of goserelin and anastrozole is an effective endocrine therapy regiment for patients with premenopausal metastatic breast cancer.It can be recommended for the premenopausal and hormone dependent mastatic breast cancer patients.
